RNA Interference for Drug R&D: Applications, Alliances, Companies and WW Market to 2011
Takeda Pacific, July 2007, Pages: 131
This report assesses the RNA interference market for drug R&D. RNA interference (RNAi) has been hailed in the science media as the hottest technical breakthrough in bioscience in the last ten years. A 2006 Nobel Prize was awarded to the two scientists that discovered this important biological effect.
RNAi allows scientists to disrupt or silence the expression of a gene being studied. RNAi can also be used as a therapeutic agent. This field has quickly emerged as a fast growing young market. The report provides the WW outlook and market trends.
This must-have report discusses how an expanding number of companies have created a vibrant commercial market that has segmented into different areas of life science research and drug R&D. The market might be worth billions in a few years.
This study reviews the market landscape and analyzes the players. The market areas studied range from life science research products and services to therapeutics or drug delivery tools for RNAi agents.
The report discusses RNAi topics including dsRNA, shRNA, siRNA, ddRNA, miRNA, RNAi-as-drug, and targeted disease areas. This study analyzes RNAi deals including M&As, alliances and examples of patent considerations. For example, a number of big pharma companies are developing drugs with RNAi and have either licensed or partnered with RNAi R&D companies. One big pharma acquired a leading RNAi developer.
This report is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and etc. The report includes 39 detailed tables and figures that provide key data about items such as strategic alliances, M&As, market size, segments and so on.
Twenty company profiles provide the reader a snapshot of the companies’ focus or activities. This PDF formatted report is searchable by using key words. Internet links help readers access companies’ own web sites for further review.
1.RNAi Market & Business Models
Overview of RNA Interference
Double Stranded RNA (dsRNA)
Small interfering RNA (siRNA)
Short Hairpin RNA (shRNA)
DNA-directed RNAi (ddRNAi)
MicroRNA (miRNA)
The RNAi Market & Key Customer Applications
The WW RNAi Market
RNAi Tools for Research, Drug Discovery & Development
As Tools for Basic Research
As Tools for Drug Discovery
As Tools for Drug Development
RNAi-as-Drugs (Therapeutics)
Competitive Market
Market Map of Major Players
Research Findings & Analysis
Market Leaders
RNAi Moves Upstream on the Drug R&D Path
Technology Big Picture
Business Model & Product Development Strategies
2.M&A and Alliance Activities
Analysis of RNAi M&As and Alliances, 2005 to July-2007
RNAi Alliances and M&As, 2005 to June-2007
Intellectual Property and Regulatory Approval
Intellectual Property
Regulatory Approval
Findings: Companies to Watch for Future R&D
RNAi Technology Companies on the Move
Big Pharma is Involved in RNAi
3.Market Forecast and Trends
The WW RNA Interference (RNAi) Market Size 2006-2011
WW RNAi Market by Segments
RNAi Market By WW Regions
RNAi Market By Application Segments
RNAi in Basic Research
RNAi in Drug Discovery
RNAi in Drug Development
RNAi Therapeutics
RNAi Application Segment Market Shares, 2007 & 2011
RNAi Market By Major Disease Segments
Cancer
Infections
Metabolic
Eye disease
CNS
Respiratory
Inflammation
Bone Diseases
Blood Disease
Cardiovascular
Diagnostics, Skin Conditions and Others
Major Disease Segment Market Shares (%), 2007 & 2011
RNAi Market By Product Segments
RNAi Reagents & Related Services
RNAi Delivery Tools & Devices
Assay Systems
Cell Lines & Related
Discovery Techs, Services & Drugs
Genomewide RNAi HT/ HC Screening Tools
RNAi Product Segment Market Shares (%), 2007 & 2011
Key Trends/ Future Directions
Big Pharma Starting to Get Involved in RNAi
Advances Made in Dealing With Off-target Effects
Growing Knowledge About microRNAs
Direct Delivery of RNAi-based Drugs
Systemic Delivery of RNAi Drugs
RNAi Future Direction Timeline
4.Selected Companies Working in RNAi
Alnylam Pharmaceuticals, Inc.
Ambion, Inc.
Avalon Pharmaceuticals, Inc.
Benitec, Ltd.
Cenix Bioscience GmbH
CytRx Corporation
Dharmacon, Inc.
Integrated DNA Technologies, Inc. (IDT)
Intradigm Corporation
Intronn, Inc.
Invitrogen Corporation
Lentigen Corporation
Mirus Bio Corporation
Nastech Pharmaceutical Company Inc.
Open Biosystems
Opko Health, Inc.
Panomics, Inc.
RNAx GmbH
Sirna Therapeutics, Inc.
Targeted Genetics Corporation
5.Findings and Suggestions
Review of Findings and Key Trends
RNAi Technology
Competitive Landscape
M&As and Alliances
Patents
Market Assessment
Recommendations to Capture Opportunities
Products Needed by RNAi Users in R&D
Future Market Prospects
6.Appendix
RNAi Glossary
Company Contacts
About Takeda Pacific
About the Authors
List of Tables
Table 1. Diseases Targeted by Direct Delivery of RNAi Drugs
Table 2. Diseases Targeted by Systemic Delivery of RNAi Drugs
Table 3. Major Players in the RNAi Market
Table 4. Major Players by Focus Segment and Product Strategy
Table 5. Summary of RNAi M&As and Alliances, 2005 to July-2007
Table 6. M&As and Alliances, Jan-July/ 2007
Table 7. M&As and Alliances, 2006
Table 8. M&As and Alliances, 2005
Table 9. RNAi Related Patent Applications (US), 2002-1H2007
Table 10. Key Patents for RNAi Reagents and Drugs
Table 11. RNAi Therapeutics In /(or Near) Clinical Trials
Table 12. Top RNAi Alliance Players: RNAi Technology Companies
Table 13. Top RNAi Alliance Players: Big Pharmas
Table 14. WW RNAi Market Size By Total Revenues ($M), 2006-2011
Table 15. WW RNAi Market By WW Regions and Revenues, 2006-2011
Table 16. WW Regions Market Shares (%), 2007 & 2011
Table 17. US RNAi Market By Application Segment Revenues ($M), 2006-2011
Table 18. Application Segment Market Shares (%), 2007 & 2011
Table 19. RNAi Market By Major Disease Segments, Revenues ($M), 2006-2011
Table 20. Major Disease Segment Market Shares (%), 2007 & 2011
Table 21. RNAi Market By Product Segments, Revenues ($M), 2006-2011
Table 22. Product Segment Market Shares (%), 2007 & 2011
Table 23. RNAi R&D Unmet Needs - Selected Opportunity Matrix
List of Illustrations
Figure 1. Timeline for Key RNAi Technology Developments
Figure 2. Central Theme of Modern Biology, DNA encodes for Proteins
Figure 3. The RNAi Process with dsRNA, shRNA, siRNA and RISC
Figure 4. RNAi R&D Market by Major Applications
Figure 5. RNAi Related Patent Applications (US), 2002-1H2007
Figure 6. New Drug Approval Timeline and Roadmap
Figure 7. WW RNAi Market Size By Total Revenues ($M), 2006-2011
Figure 8. WW RNAi Market By WW Regions and Revenues, 2006-2011
Figure 9. WW RNAi Market By WW Regions and Shares, 2007 & 2011
Figure 10. WW RNAi Market By Application Segment Revenues, 2006-2011
Figure 11. RNAi Application Segment Market Shares (%), 2007 & 2011
Figure 12. RNAi Market By Major Disease Segments, Revenues ($M), 2006-2011
Figure 13. Major Disease Segment Market Shares (%), 2007 & 2011
Figure 14. RNAi Market By Product Segments, Revenues ($M), 2006-2011
Figure 15. Product Segment Market Shares (%), 2007 & 2011
Figure 16. RNAi Future Direction Timeline to 2011
Alnylam Pharmaceuticals, Inc.
Ambion, Inc.
Avalon Pharmaceuticals, Inc.
Benitec, Ltd.
Cenix Bioscience GmbH
CytRx Corporation
Dharmacon, Inc.
Integrated DNA Technologies, Inc. (IDT)
Intradigm Corporation
Intronn, Inc.
Invitrogen Corporation
Lentigen Corporation
Mirus Bio Corporation
Nastech Pharmaceutical Company Inc.
Open Biosystems
Opko Health, Inc.
Panomics, Inc.
RNAx GmbH
Sirna Therapeutics, Inc.
Targeted Genetics Corporation
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
